Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Proteins patents

      

This page is updated frequently with new Proteins-related patent applications.




Date/App# patent app List of recent Proteins-related patents
08/18/16
20160238615 
 Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip patent thumbnailSolid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip
Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University


08/18/16
20160238614 
 Process for ultra-sensitive quantification of target analytes in complex biological systems patent thumbnailProcess for ultra-sensitive quantification of target analytes in complex biological systems
Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment.
Battelle Memorial Institute


08/18/16
20160238612 
 High-throughput single molecule protein identification patent thumbnailHigh-throughput single molecule protein identification
The present invention is methods and assays for identifying single proteins from a sample, without the use of affinity reagents. The methods and assays combine endopeptidase-based component of conventional peptide mapping with single molecule labeling and a microreactor array platform.
The Trustees Of Columbia University In The City Of New York


08/18/16
20160238608 
 Human cancer-related gene, its encoded products and applications patent thumbnailHuman cancer-related gene, its encoded products and applications
The invention discloses a human cancer-related gene, laptm4b, its encoded products and their applications thereof. This human cancer-related gene provided by this invention comprises one of the following nucleotide sequences: (1) seq id no: 1, seq id no: 2, seq id no: 3, seq id no: 6, or seq id no: 8 in the sequence listings; (2) polynucleotides that encode the protein sequences of seq id no: 4, seq id no: 5, or seq id no: 7 in the sequence listings; (3) dna sequences having above 90% homology with the dna sequences specified by seq id no: 1, seq id no: 2, seq id no: 3, seq id no: 6, or seq id no: 8 in the sequence listings, and these dna sequences encode the proteins with the same or similar functions.
Peking University


08/18/16
20160238602 
 Method for detecting proteins by means of aptamers patent thumbnailMethod for detecting proteins by means of aptamers
The present invention describes a method for an in vitro detection of a first protein in a sample, comprising the steps of: a) separating the sample by means of a native separation method; b) transferring the separated sample onto a membrane; c) contacting the membrane with an aptamer which specifically binds to the first protein; and d) detecting the first protein by detecting the aptamer bound to the first protein.. .
Technische Universität Berlin


08/18/16
20160238600 
 Method for selecting a single cell expressing a heterogeneous combination of antibodies patent thumbnailMethod for selecting a single cell expressing a heterogeneous combination of antibodies
Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


08/18/16
20160238594 
 Methods and compositions for quantifying metabolites and proteins from single cells patent thumbnailMethods and compositions for quantifying metabolites and proteins from single cells
Methods and compositions for quantifying the cellular concentration of cyclic adenosine monophosphate (camp), cyclic guanine monophosphate (cgmp), glutathione, glucose, and glutamine in a single cell include the use of conjugates and analogs in immunofluorescent assays for on-chip quantification. These metabolite immunofluorescent assays may be incorporated with proteomic assays for simultaneous single cell analysis of metabolites and proteins..
California Institute Of Technology


08/18/16
20160238591 
 Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins patent thumbnailBiopolymer-mediated assembly of nanoparticles using genetically encoded proteins
Various aspects and embodiments provided herein are directed to compositions that include at least one nanoparticle linked to a first polypeptide, and a biologically synthesizable polymer linked to at least one second polypeptide that binds covalently to the first polypeptide. Other aspects and embodiments provided herein are directed to methods of producing the foregoing compositions and components therein..
Massachusetts Institute Of Technology


08/18/16
20160237476 
 System and  laser lysis patent thumbnailSystem and laser lysis
Systems and methods for in situ laser lysis for analysis of biological tissue (live, fixed, frozen or otherwise preserved) at single cell resolution in 3d. For example, a system and method for lysing individual cells in situ, including the steps of capturing a tissue sample comprising a cellular content, subjecting the tissue sample to a stream of continuous fluid flow, lysing a selected area of the tissue sample with a laser, thereby releasing at least a portion of the cellular content from the tissue sample, recovering at least one target molecule from the cellular content in the stream, and processing at least one target molecule is provided.
Arizona Board Of Regents On Behalf Of Arizona State University


08/18/16
20160237469 
 Microbial analysis patent thumbnailMicrobial analysis
The present invention is concerned with a method of identifying microbial strains (e.g. From a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % meoh; ii) a sample preparation step, comprising preparation of a maldi sample incorporating the extracted lipids; iii) a data gathering step, comprising performing maldi-based mass spectrometry on the maldi sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain.
Kratos Analytical Limited


08/18/16
20160237466 

Multiple proteases deficient filamentous fungal cells and methods of use thereof


The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.. .
Glykos Finland Oy


08/18/16
20160237423 

Methods for the selection of binding proteins


This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
Bristol-myers Squibb Company


08/18/16
20160237414 

Lysosomal protein targeting sequence and therapeutic applications of same


The present disclosure relates to methods of treating diseases states such as lysosomal storage diseases and/or neurodegenerative diseases. Also disclosed are one or more compositions that may be useful for one or more of the disclosed methods, including compositions that may comprise acid β-glucosidase (gcase) protein comprising one or more mutations, peptides of acid β-glucosidase, and dna vectors and cell lines related to acid β-glucosidase peptides or proteins..
Children's Hospital Medical Center


08/18/16
20160237334 

Method of using biosurfactants as acid corrosion inhibitors in well treatment operations


Corrosive effects arising during well treatment applications are inhibited and/or prevented by introducing into the well composition containing a corrosion inhibitor of a biosurfactant selected from glycolipids (other than sophorolipids and mannosylerythritol lipids), phospholipids; polyol lipids; lipoproteins, lipopeptides, ornithine lipids, carbohydrate-lipids, neutral lipids, aminoacid lipids, exolipids, liposan; siderolipids, protein polyamines diglycosyl diglycerides, fimbriae, saponified triglycerides and fatty acids. The composition may also contain a corrosion inhibitor intensifier..
Baker Hughes Incorporated


08/18/16
20160237156 

Immunoglobulin fusion proteins and compositions thereof


Disclosed herein are immunoglobulin fusion proteins that have a first antibody region attached to an extender fusion region. The extender fusion region contains a therapeutic agent and a beta strand secondary structure.
The Scripps Research Institute


08/18/16
20160237155 

Targeted/immunomodulatory fusion proteins and methods for making same


The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.. .
Biocon Limited


08/18/16
20160237149 

Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins


Provided herein is a method for producing an antibody, such as an anti-tnfα antibody (e.g., infliximab) having a c-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with dna encoding the antibody in a culture medium comprising at least 0.5 μm zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.. .
Janssen Biologics B.v.


08/18/16
20160237142 

Synthetic single domain antibody


The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d ab) and its use in generating synthetic single domain antibody library (hs2d ab-l1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics..
Centre National De La Recherche Scientifique - Cnrs


08/18/16
20160237135 

Interleukin-4 receptor-binding fusion proteins and uses thereof


The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic bcl-2 family member protein moiety..
Medicenna Therapeutics Pte Ltd


08/18/16
20160237133 

Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use


The present disclosure provides chimeric proteins having an n-terminus coupled to a c-terminus, wherein the n-terminus comprises an n-terminal portion of fibroblast growth factor (fgf) 2 and the c-terminus comprises a portion of an fgf1 protein. Such fgf2/fgf1 chimeras can further include a fibroblast growth factor receptor (fgfr) 1c-binding protein, a β-klotho-binding protein, or both.
Salk Institute For Biological Studies


08/18/16
20160237132 

Fusion polypeptides comprising mucin-domain polypeptide linkers


The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans..
Alkermes, Inc.


08/18/16
20160237130 

Apelin fusion proteins and uses thereof


The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain.
Regeneron Pharmaceuticals, Inc.


08/18/16
20160237126 

Light-activated chimeric opsins and methods of using the same


Provided herein are compositions comprising light-activated chimeric proteins expressed on plasma membranes and methods of using the same to selectively depolarize excitatory or inhibitory neurons.. .
The Board Of Trustees Of The Leland Stanford Junior University


08/18/16
20160237125 

Proteins with diagnostic and therapeutic uses


The present invention provides a recombinant protein capable of binding to complement factor h (cfh), and thereby inducing increased binding of c3d and c3b by bound cfh compared to unbound cfh. Methods and medical devices for using utilising the same are also described..
The University Court Of The University Of Edinburg


08/18/16
20160237124 

Kind of mutated proteins a with high alkali resistance feature and application thereof


A series of protein a mutants having high alkali resistance, and methods of using the protein a mutants are provided. The protein a mutants have a high binding affinity for regions of immunoglobulin proteins other than the complementarity determining regions.
Nanjing Genscript Co., Ltd.


08/18/16
20160237122 

Fusion protein for hiv-1 gp120 antigen detection


The present disclosure relates to novel fusion proteins that bind to the hiv-1 gp120 antigen. The present disclosure also relates to nucleic acids, plasmids and host cells that comprise a sequence that encodes the fusion proteins of the disclosure.
Arizona Board Of Regents, For And On Behalf Of, Arizona State University


08/18/16
20160237120 

Polyomavirus peptide sequences


The current invention concerns the identification of b-cell epitopes (as linear peptides) from human polyoma virus proteins and their use in an immune diagnostic assay.. .
Janssen Diagnostics Bvba


08/18/16
20160237116 

Site-specific chemoenzymatic protein modifications


The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses..
Novartis Ag


08/18/16
20160237114 

Protein affinity purification resins with tagged protein


Disclosed herein are protein enrichment substrates and methods for making the same that can be used to enrich proteins of interest. Also disclosed herein are methods for protein purification using these protein enrichment substrates..
Purdue Research Foundation


08/18/16
20160237111 

Downstream bioprocessing device


Large-scale downstream processing of secreted recombinant proteins is provided in a single device, wherein the contents of a plurality of bioreactors are combined simultaneous to their harvesting and purification resulting in significant savings of time and the cost of manufacturing.. .
Therapeutic Proteins International, Llc


08/18/16
20160235833 

Chimeric factor h binding proteins (fhbp) and methods of use


Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


08/18/16
20160235830 

Chimeric ospa genes, proteins and methods of use thereof


The invention relates to the development of chimeric ospa molecules for use in a new lyme vaccine. More specifically, the chimeric ospa molecules comprise the proximal portion from one ospa serotype, together with the distal portion from another ospa serotype, while retaining antigenic properties of both of the parent polypeptides.
Brookhaven Science Associates, Llc


08/18/16
20160235825 

Formulation for oral administration of proteins


Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and gi tract by the addition of an antioxidant.. .
Alvine Pharmaceuticals, Inc.


08/18/16
20160235813 

Anti-inflammatory proteins and methods of use


A method and composition for reducing or alleviating inflammation in a subject is provided, including administering to the subject a therapeutically effective amount; of one or more isolated proteins respectively comprising an amino acid sequence set forth in seq id nos:1-31, or a biologically active fragment or variant thereof or combinations of these to thereby reduce or alleviate inflammation. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease..
James Cook University


08/18/16
20160235810 

Methods of treating diabetes and related disorders


The invention relates to methods of treating metabolic conditions, including type 2 diabetes mellitus, by administering prolactin-inducible protein (pip) or fusion proteins, analogs or variants of pip with altered or truncated pip sequence, site-specific mutants, or chemically modified mutants including pharmaceutical properties comprising the same.. .
Novartis Ag


08/18/16
20160235760 

Methods of treatment using selective bcl-2 inhibitors


This invention pertains to methods of treating systemic lupus erythematosus and sjogren's syndrome with compounds that selectively inhibit the activity of bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of bcl-2 proteins, with a lesser affinity for inhibiting the activity of other bcl-2 family proteins, including bcl-xl.
Abbvie Inc.


08/18/16
20160235731 

Methods to induce targeted protein degradation through bifunctional molecules


The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders.
Dana-farber Cancer Institute, Inc.


08/18/16
20160235730 

Methods to induce targeted protein degradation through bifunctional molecules


The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders.
Dana-farber Cancer Institute, Inc.


08/18/16
20160235672 

Reconstituted high density lipoproteins composition and uses thereof


A reconstituted high density lipoprotein composition including negatively charged phospholipids enhances cholesterol clearance, reduces inflammation and other anti-atherosclerotic actions.. .
Universite Pierre Et Marie Curie - Paris 6 (upmc)


08/18/16
20160235645 

Guar protein extracts and compositions comprised thereof as surface treating and/or modifying agents


Surface treating and/or modifying compositions, for example cosmetic or pharmaceutical or plant protective compositions or domestic care compositions comprise a guar protein extract, or derivative thereof, such guar protein extract comprising at least 65% by weight of proteins and are particularly suitable as surface treating and/or modifying agents, wherein these surfaces are, for example, the skin, hairs, domestic care and textile surfaces and plant leaf surfaces.. .
Rhodia Chimie


08/18/16
20160235082 

Heat stable whey protein products and a process for the preparation of heat stable whey proteins


Different versions of heat stable whey protein ingredients can be produced by subjecting whey protein solutions to specific heat treatments in the presence of a specific concentration of hydrogen peroxide. The whey protein ingredients including heat stable liquid retentate of wpi, wpc or any other form of whey protein ingredients, and heat stable powders of wpi or wpc or any other whey protein powders can be prepared by heat treatment of a whey protein solution mixed with a hydrogen peroxide solution.
South Dakota State University


08/11/16
20160232293 

Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers


Disclosed are methods based on correlation of drug effects with genetic alterations in specific sub-regions of proteins. The presence of such genetic alterations in subjects with a relevant disease allows more directed treatment of the disease, ideally limited to subjects having a genetic alteration in the drug effect-correlated sub-region of a protein.
Sanford-burnham Medical Research Institute


08/11/16
20160232292 

Methods, systems, and computer program products for implementing knowledge base-driven generation of immunoassay protocols and procedures


Disclosed are techniques for implementing knowledge base-driven generation of immunoassay protocols and procedures. These techniques invoke an expert system or knowledge engineering base to identify or determine one or more proteins of interest for one or more tumor types of interest or a disease group of interest and further invoke a protocol generation module that is stored at least partially in memory and includes or functions in tandem with one or more processors of a computing system to generate a concurrent or a sequential immunoassay protocol based in part or in whole upon one or more immunoassay protocol rules and the one or more tumor types of interest or a disease group of interest.

08/11/16
20160232279 

System and methods for disease module detection


The present disclosure discusses a system and method for disease module detection. More particularly, a protein network and list of seed proteins are provided to the system.
Northeastern University


08/11/16
20160231330 

Biomarkers related to organ function


Disclosed herein are methods of identifying biomarkers (such as genes (e.g., rna or mrna), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


08/11/16
20160231328 

Human fc-bearing igg antibodies to polyethylene glycol


Polyethylene glycol (peg) is often conjugated with therapeutic proteins to enhance their pk properties. Peg may, however, be immunogenic, and the presence of peg in food and cosmetics is believed to result in pre-existing anti-peg antibodies in humans.
Bristol-myers Squibb Company


08/11/16
20160230228 

Compositions and methods for detecting and treating neurological conditions


The present invention relates to the nipa-1 proteins and nucleic acids encoding the nipa-1 proteins. The present invention further provides assays for the detection of nipa-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of nipa-1 proteins..
The Trustees Of The University Of Pennsylvania


08/11/16
20160230219 

Method for nucleic acid analysis from a region of interest in a biological sample


The invention discloses a method for determining a nucleotide sequence of a nucleic acid segment present in a biological sample, comprising the steps of: a) generating a fluorescent image of the sample by a protocol comprising immunofluorescence detection of at least five different target proteins in the sample; b) selecting a region of interest of the sample by comparing the image to a predetermined criterion; c) removing a subsample from the region of interest, and; d) determining a nucleotide sequence of a nucleic acid segment present in the subsample.. .
Ge Healthcare Bio-sciences Corp.


08/11/16
20160230205 

Activated formylglycine-generating enzymes and methods of producing and using the same


The present disclosure provides activated formylglycine-generating enzymes (fge), methods of producing activated fge, and their use in methods of producing a protein comprising a formylglycine (fgly) residue. The methods of producing activated fge, as well as methods of use of activated fge in producing fgly-containing proteins, include both cell-based and cell-free methods.
R.p. Scherer Technologies, Llc


08/11/16
20160230204 

Metabolically optimized cell culture


Improved methods for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, the method provides for culturing cells that have metabolically shifted.
Regeneron Pharmaceuticals, Inc.


08/11/16
20160230203 

Portable fluidic platform for rapid cell-free production of protein biologics


A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications.
Leidos, Inc.


08/11/16
20160230202 

Process for generating synthetic engineered recombinant proteins for vaccination, diagnosis and treatment of disease


A process for generating a synthetic engineered recombinant protein has been performed by providing an original protein design and the necessary probabilistic priors for random in silico assembly. Once the in silico synthetic protein is assayed using mathematic modeling, the proteins are then reverse translated into dna.

08/11/16
20160230184 

Herbicide-resistant sunflower plants, polynucleotides encoding herbicide-resistant acetohydroxyacid synthase large subunit proteins, and methods of use


Herbicide-resistant sunflower plants, isolated polynucleotides that encode herbicide-resistant and wild-type acetohydroxyacid synthase large subunit (ahasl) polypeptides, and the amino acid sequences of these polypeptides, are described. Expression cassettes and transformation vectors comprising the polynucleotides of the invention, as well as plants and host cells transformed with the polynucleotides, are described.
Nidera S.a.


08/11/16
20160230183 

Transgenic plants with enhanced agronomic traits


This invention provides recombinant dna constructs, transgenic plant nuclei and cells with such recombinant dna construct for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
Monsanto Technology Llc


08/11/16
20160230177 

E. coli separatome-based protein expression and purification platform


Provided is a separatome-based peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome of e. Coli.
Board Of Trustees Of The University Of Arkansas


08/11/16
20160229910 

Tm4sf1 binding proteins and methods of using same


This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


08/11/16
20160229906 

Mice that produce antigen-binding proteins with ph-dependent binding characteristics


Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


08/11/16
20160229905 

Modified anti-inflammatory proteins and use


A modified ac-tmp-2 protein lacks one or a plurality of acidic c-terminal amino acids normally present in a full-length or wild-type ac-tmp-2 protein and may also lack one or a plurality of n-terminal amino acids while retaining the amino acid sequence c—s—c at or near the n-terminus. The modified ac-tmp-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject.
James Cook University


08/11/16
20160229904 

Optimized human clotting factor viii gene expression cassettes and their use


The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to factor viii proteins containing modifications in the amino acid sequence of the factor viii protein, as well as nucleic acid constructs encoding the factor viii proteins and methods of using these compositions to treat a bleeding disorder..
The University Of North Carolina At Chapel Hill


08/11/16
20160229903 

Thrombin cleavable linker


The present invention provides a chimeric molecule comprising a vwf protein fused to a heterologous moiety via a vwf linker. The invention provides an efficient vwf linker that can be cleaved in the presence of thrombin.
Biogen Ma Inc.


08/11/16
20160229901 

Interleukin-2 fusion proteins and uses thereof


The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a bcl-2 family member protein moiety..
Medicenna Therapeutics Pte Ltd


08/11/16
20160229899 

Lucigen yellow (lucy), a yellow fluorescent protein


Described herein are isolated polynucleotides that encode a fluorescent protein which is at least 80% sequence identical to a protein selected from the group consisting of seq. Id.
Lucigen Corporation


08/11/16
20160229898 

Fusion proteins, cells, and kits for characterizing botulinum toxin


Compositions for characterization of botulinum toxin (bont) are described that include a genetically modified cell that is transfected with an artificial construct comprising a nucleic acid sequence that encodes for a hybrid protein having (a) a reporter-containing portion chemically coupled to (b) a cleavage site and (c) a control fluorophore. The cleavage site interacts with a bont in a manner that cleaves the reporter-containing portion from remainder of the construct.
Biomadison, Inc.


08/11/16
20160229896 

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses


A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific t cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain, located at the n-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to seq id no: 4, 2, 3, or 6, located at the c-terminus of the apc-binding domain or the cd91 receptor-binding domain; and (c) an antigen of a pathogen, located at the c-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of seq id no: 13; and (e) an endoplasmic reticulum retention sequence, located at the c-terminus of the fusion protein..
Thevax Genetics Vaccine Co., Ltd.


08/11/16
20160228659 

Dry powder inhaler and system for drug delivery


A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler.
Mannkind Corporation


08/11/16
20160228544 

Single walled carbon nanotube polynucleotide complexes and methods related thereto


The present invention provides single-walled carbon nanotube formulations for the delivery of bioactive agents including large polynucleotides encoding therapeutic proteins into hard-to-transfect cells and methods of making such single-walled carbon nanotube formulations.. .
Ensysce Biosciences, Inc.


08/11/16
20160228521 

Managing immune responses in transplantation


The present invention provides, among other things, methods of treatment of donor and/or host subjects prior to, during, and/or after transplantation of donor tissue into the host subject with nanoparticle compositions encapsulating tissue components to usefully manage immune responses associated with transplantation. In some embodiments, methods include administering to a recipient organism who has received or will receive a transplant of one or more heterologous tissue components from a donor organism a composition including encapsulated donor organism tissue components.
Allertein Therapeutics, Llc


08/11/16
20160228514 

Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases


The present invention relates to methods to treat a neurodegenerative disease or disorder, e.g., a motor neuron disease in a subject, whereby the subject is administered a recombinant human mullerian inhibiting substance (mis) protein as disclosed herein, wherein the recombinant human mis protein comprises a modified kex cleavage site for increased cleavage. The recombinant human mis protein can be produced from a pre-proprotein comprising a non-mis leader sequence or a functional fragment thereof in place of the mis leader sequence..
University Of Massachusetts


08/11/16
20160228512 

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn-lambda ligands engage a novel receptor ifn-lambdar1 (crf2-12) and il-10r2 (crf2-4) for signaling and induction of biological activities


A novel ifn-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated inf-λ1, ifn-λ2, ifn-λ3, based inter alia, in their ability to induce antiviral protection.
Rutgers, The State University Of New Jersey


08/11/16
20160228451 

Rock in combination with mapk pathway


The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer.
Stichting Het Nederlands Kanker Instituut


08/11/16
20160228410 

An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells


The present invention provides the compound ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like c/ebpα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (gcsfr).
Council Of Scienticfic & Industrial Research


08/04/16
20160223569 

Novel non-invasive methods of monitoring hiv viral loads


The present invention provides a method of assessing or monitoring systemic hiv viral load in an hiv-infected human patient. In certain embodiments, the method comprises analyzing a sample comprising urine from the patient for the presence and/or concentration of at least one protein selected from a specific group of proteins..
Drexel University


08/04/16
20160223561 

Methods and kits for isolation and analysis of a chromatin region


The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas


08/04/16
20160223560 

Methods and compositions for identifying d-peptidic compounds that specifically bind target proteins


Methods and compositions for identifying d-peptidic compounds that specifically bind target proteins are provided. Aspects of the methods include screening libraries of 20 residue or more l-peptidic compounds for specific binding to 40 residue or more d-target proteins.
The Governing Council Of The University Of Toronto


08/04/16
20160223554 

Methods for diagnosis, prognosis and methods of treatment


The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population.
Nodality, Inc.


08/04/16
20160223545 

Methods of screening for janus kinase 3 interacting compounds


The present invention provides a method for screening compounds for their ability to inhibit autophosphorylation of janus kinase 3 in the absence of any additional substrate. The present invention also provides a method for screening compounds that bind to janus kinase 3 domains other than the kinase domain, to identify synthetic or natural compounds including biomolecules, that modulate janus kinase 3 activity.

08/04/16
20160222462 

Analysis of apoptotic bodies in bodily fluids


The invention provides methods for the detection of apoptotic bodies in bodily fluid, including blood, blood plasma, and serum. The invention provides methods of labeling apoptotic bodies and their proteins, nucleic acids, and phospholipids.
Oncomedx, Inc.


08/04/16
20160222450 

Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof


The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection..
Celera Corporation


08/04/16
20160222442 

Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids


The invention provides miniaturized lateral flow chromatographic and lateral flow chromatographic microarray devices (lfm). The miniaturization of lateral flow nucleic acid detection achieved by the present invention offers reduced reagent use, femtomole sensitivity, excellent linear dynamic range, and rapid detection.
Los Alamos National Security, Llc.


08/04/16
20160222428 

Method for producing metabolites, peptides and recombinant proteins


The present invention relates to a method for producing a molecule of interest in bacteria which is based on a reversible growth arrest of the bacteria at the cellular growth global control system level, thus allowing an improved yield of production of said molecule of interest.. .
Universite Joseph Fourier - Grenoble 1


08/04/16
20160222421 

Enzymatic digestion of microalgal biomass for lipid, sugar, and protein recovery


Methods for the recovery of lipids, sugars, and proteins from microbial biomass by enzymatic digestion are disclosed. The methods involve treating microalgae with a fungal acid protease, or with a mixture of at least one protease and at least one amylase..
The University Of Toledo


08/04/16
20160222416 

Orthogonal cas9 proteins for rna-guided gene regulation and editing


Methods of modulating expression of a target nucleic acid in a cell are provided including use of multiple orthogonal cas9 proteins to simultaneously and independently regulate corresponding genes or simultaneously and independently edit corresponding genes.. .
President And Fellows Of Harvard College


08/04/16
20160222403 

Herbicide-resistant sunflower plants, polynucleotides encoding herbicide-resistant acetohydroxyacid synthase large subunit proteins, and methods of use


Herbicide-resistant sunflower plants, isolated polynucleotides that encode herbicide-resistant and wild-type acetohydroxyacid synthase large subunit (ahasl) polypeptides, and the amino acid sequences of these polypeptides, are described. Expression cassettes and transformation vectors comprising the polynucleotides of the invention, as well as plants and host cells transformed with the polynucleotides, are described.
Nidera S.a.


08/04/16
20160222379 

Use of multiple recombination sites with unique specificity in combinational cloning


The present invention provides compositions and methods for recombinational cloning. The compositions include vectors having multiple recombination sites with unique specificity.
Life Technologies Corporation


08/04/16
20160222374 

Methods for modulating the activity of insecticidal proteins


Compositions and methods for controlling pests are disclosed. In particular, methods for modulating the activity of cry1ba proteins against lepidopteran or coleopteran pests are provided.
Syngenta Participations Ag


08/04/16
20160222370 

Recombinant yeast host cell with fe-s cluster proteins and methods of using thereof


Yeast strains were engineered that have increased activity of heterologous proteins that require binding of an fe—s cluster for their activity. The yeast strains have reduced activity of an endogenous fe—s protein.
Butamax Advanced Biofuels Llc


08/04/16
20160222364 

Modified zinc finger binding proteins


Disclosed herein are compositions and method comprising non-canonical (e.g., non-c2h2) zinc finger proteins.. .
Sangamo Biosciences, Inc.


08/04/16
20160222341 

System and production of on-demand proteins in a portable unit for point of care delivery


A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery..
University Of Maryland, Baltimore County


08/04/16
20160222337 

Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly


A method for promoting biological activity uses a filter system to increase cell production of a fed batch bioreactor. The filter system cycles bioreactor fluid through a hollow fiber tangential flow filter which separates metabolic wastes (as well as proteins) from cells produced in bioreactor and returned to fed batch bioreactor, improving cell production in the fed batch bioreactor.

08/04/16
20160222174 

Method and compositions for synthesizing improved silk fibers


The present disclosure provides methods and compositions for directed to synthetic block copolymer proteins, expression constructs for their secretion, recombinant microorganisms for their production, and synthetic fibers (including advantageously, microfibers) comprising these proteins that recapitulate many properties of natural silk. The recombinant microorganisms can be used for the commercial production of silk-like fibers..
Bolt Threads, Inc.


08/04/16
20160222112 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222111 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222110 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222109 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222108 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222101 

Protein formulations and methods of making same


The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients.
Abbvie Inc.


08/04/16
20160222100 

Method of treating glioma


Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (bdnf), or brevican, to a patient with a glioma.
The Board Of Trustees Of The Leland Stanford Junior University


08/04/16
20160222075 

Production of glycoproteins using manganese


Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.. .
Amgen Inc.


08/04/16
20160222072 

Universal protein tag for double stranded nucleic acid delivery


Disclosed herein are chimeric proteins that include one or more double stranded nucleic acid binding domains (dsnabd) and one or more polyhis domains, and compositions that further include a therapeutic double stranded nucleic acid and a targeting ligand bound to the therapeutic double stranded nucleic acid, wherein the dsnabd of the chimeric protein is bound to the therapeutic double stranded nucleic acid, and uses of the compositions to treat disease.. .
University Of Washington Through Its Center For Commercialization


08/04/16
20160222070 

Compounds and methods for diagnosis and immunotherapy of tuberculosis


Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more mycobacterium proteins and dna molecules encoding such polypeptides.
Corixa Corpoation


08/04/16
20160222069 

Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species


The invention relates to three isolated dna molecules that encode for proteins, bigl1, bigl2 and bigl3, in the leptospira sp bacterium which have repetitive bacterial-ig-like (big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for bigl1, bigl2 and bigl3 proteins are used for the diagnosis and prevention of infection with leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance..
Fundação Oswaldo Cruz - Fiocruz


08/04/16
20160222068 

Constructs for expressing biological molecules that integrate into bacterial microcompartments


A conserved region of sequence in bacterial microcompartment (bmc) enzymes and proteins was identified. Peptide sequences derived from this conserved region of native bmc proteins and enzymes appear to target the hexameric facets of bmc shell proteins.
The Regents Of The University Of California


08/04/16
20160222067 

Novel aav's and uses thereof


The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses.
University Of Massachusetts


08/04/16
20160222066 

Norovirus derived immunogenic compositions and methods


The invention relates to chimeric norovirus vp1 proteins containing the s-domain of vp1 of a first norovirus strain and a p-domain that contains at least a portion of the p-domain of vp1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric vp1 proteins, virus-like particles that contain a chimeric norovirus vp1 protein, and to immunogenic compositions.
Novartis Ag


08/04/16
20160222058 

Bioactive peptides and methods of producing and using the same


Described herein are methods of identifying and releasing bioactive peptides from their full length proteins. The method involves (a) contacting the protein with a reducing agent, a sonication step, a high pressure processing step, a heating step, a fermentation step, or any combination thereof; and (b) contacting the protein after step (a) with a hydrolytic enzyme to produce the bioactive peptide.
The Governors Of The University Of Alberta






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9118

5962

1 - 1 - 132